Considering that PSMA radiopharmaceuticals currently dominate the theranostic landscape but also have some limitations, particularly in patients with low or heterogeneous PSMA expression profiles [52,53], we developed a multimodal TM directed against an alternative PCa-specific target, PSCA, that could complement existing PSMA-directed theranostic strategies. Here, FOLH1 is linked to posterior cortical atrophy.